ABSTRACT
Endogenous sulfatide, such as 3-sulfated galactosylceramide (3-sulfatide) has been reported to be involved in neuronal development and regulation of tumor cell metastasis. Recently, a new 6-sulfated glucosylceramide (6-sulfatide) has been isolated from the ascidian, Ciona intestinalis. To determine the antitumor function of the new sulfatide, we examined the effects of synthetic 6-sulfatide and 3-sulfatide on the metastatic features of a murine melanoma cell line, B16F10. Both sulfatides significantly inhibited the adhesion of melanoma cells onto fibronectin-coated tissue plates and, the motility and invasion of the cells, with 6-sulfatide showing stronger inhibitory activities. In addition, both sulfatides inhibited α(5)-, and ß(1)- but not α(v)- or ß(3)-integrin expression. Furthermore, these sulfatides inhibited the activation of focal adhesion kinase, Akt, and extracellular signal-regulated kinase signaling pathways, which are thought to be important for cell migration and invasion. Therefore, these sulfatides may serve as promising drug candidates for the treatment of cancer metastasis.
Subject(s)
Antineoplastic Agents/pharmacology , Sulfoglycosphingolipids/pharmacology , Animals , Cell Adhesion/drug effects , Cell Line, Tumor , Cell Movement/drug effects , Extracellular Signal-Regulated MAP Kinases/antagonists & inhibitors , Fibronectins/metabolism , Focal Adhesion Protein-Tyrosine Kinases/antagonists & inhibitors , Integrin alpha5/metabolism , Integrin beta1/metabolism , Melanoma, Experimental/metabolism , Melanoma, Experimental/pathology , Mice , Neoplasm Invasiveness , Proto-Oncogene Proteins c-akt/antagonists & inhibitorsABSTRACT
Proteolipid protein 2 (PLP2) promotes the metastasis of B16F10 cells in an experimental metastasis model. However, the effect of PLP2 on spontaneous metastasis has yet to be demonstrated, and whether PLP2 may become a new therapeutic target for malignant tumors is as yet unknown. In this study, PLP2 or focal adhesion kinase (FAK) microRNA-based short hairpin RNAs (miRNAs) were used as target molecules to specifically reduce the expression of PLP2 or FAK in B16BL6 cells. In vitro, the knockdown of PLP2 or FAK significantly inhibited cell proliferation, adhesion, migration and invasion. In a spontaneous metastatic tumor model using a footpad injection, the knockdown of PLP2 or FAK markedly inhibited the proliferation of the primary tumor and prevented tumor cells from invading the popliteal lymph nodes. The results indicate that downregulation of PLP2 or FAK may improve outcomes of malignant tumor therapy.
ABSTRACT
To examine the effects of carbon ion and gamma ray irradiation on cancer-induced osteoclastogenesis, mouse calvaria MC3T3-E1 cells were cultured with conditioned medium from irradiated and non-irradiated MCF7 human breast cancer cells. The authors examined RANKL and OPG mRNA expression in osteoblastic MC3T3-E1 cells following treatment with conditioned MCF7 medium. Co-cultured MC3T3-E1 and bone marrow cells treated with conditioned medium from irradiated MCF7 cells showed decreased numbers of osteoclasts, assessed using TRAP staining. Conditioned medium from control MCF7 cells elevated the RANKL/OPG mRNA ratio in MC3T3-E1 cells; this effect was suppressed by carbon ion irradiation of the MCF7 cells. These data demonstrate that indirect interactions between breast cancer cells and MC3T3-E1 cells induce osteoclastogenesis in vitro through modulation of RANKL expression and that this process is suppressed by carbon ion irradiation.
Subject(s)
Bony Callus/radiation effects , Breast Neoplasms/pathology , Carbon/therapeutic use , Gamma Rays/therapeutic use , Osteogenesis/radiation effects , 3T3 Cells , Animals , Bone Neoplasms/etiology , Bone Neoplasms/metabolism , Bone Neoplasms/pathology , Breast Neoplasms/metabolism , Female , Gene Expression Regulation/radiation effects , Heavy Ion Radiotherapy , Humans , Mice , RNA, Messenger/metabolism , RNA, Messenger/radiation effects , Receptor Activator of Nuclear Factor-kappa B/metabolism , Receptor Activator of Nuclear Factor-kappa B/radiation effectsABSTRACT
Mast cells play a key role in allergic inflammation by releasing various mediators, such as histamine, serotonin, leukotrienes and cytokines. A signaling cascade of events activated by stimulation with antigens contributes to the regulation of mast cell degranulation. While various anti-inflammatory and anti-allergic drugs have been developed that inhibit degranulation of mast cells, the inhibitory mechanism has been poorly understood. Licochalcone A (Lico A) is a retrochalcone isolated from the root of Xinjiang liquorice and has been reported to exhibit various biological activities such as anti-inflammatory activity. We examined the effects of Lico A and related chalcones on degranulation in a rat basophilic leukemia cell line, RBL-2H3. Whereas Lico A and licochalcone C (Lico C) exhibited inhibitory activity with cytotoxicity, licochalcone D (Lico D) significantly inhibited the degranulation in RBL-2H3 cells with low cytotoxicity. Moreover, Lico D significantly inhibited the Ca2+ influx and phosphorylation of extracellular signal regulated kinase (ERK) and MEK. These results suggest that Lico D inhibits mast cell degranulation via the inhibition of both extracellular Ca2+ influx and activation of the MEK-ERK pathway.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Basophils/drug effects , Chalcones/pharmacology , Extracellular Signal-Regulated MAP Kinases/metabolism , Phytotherapy , Animals , Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/isolation & purification , Basophils/immunology , Basophils/metabolism , Basophils/pathology , Calcium/metabolism , Cell Degranulation/drug effects , Cell Line, Tumor , Chalcones/chemistry , Chalcones/isolation & purification , Cytoprotection , Extracellular Signal-Regulated MAP Kinases/genetics , Glycyrrhiza/immunology , Intracellular Space/metabolism , Phosphorylation/drug effects , Plant Roots , Rats , Signal Transduction/drug effects , Structure-Activity Relationship , Tyrosine/metabolismABSTRACT
Glycyrrhiza inflata has been used as a traditional medicine with anti-inflammatory activity. Previously, we reported that a major component, Licochalcone A, potently inhibited TNFalpha-induced NF-kappaB activation by inhibiting IKKbeta activation. In this study, we investigated whether the fixed structure of Licochalcone A by alpha, beta-unsaturated ketone is required for its inhibitory effect of NF-kappaB activation. Interestingly, reduced Licochalcone A, which lacks a double bond, failed to inhibit TNFalpha-induced NF-kappaB activation. Whereas Licochalcone A potently inhibited TNFalpha-induced IKK activation, IkappaBalpha degradation, nuclear localization of NF-kappaB and its DNA binding activity, no inhibitory effect was observed by reduced Licochalcone A. In addition, TNFalpha-induced expression of inflammatory cytokines, CCL2/MCP-1 and CXCL1/KC, was clearly inhibited by Licochalcone A but not reduced Licochalcone A. As a result, culture media pretreated with Licochalcone A but not reduced Licochalcone A following TNFalpha stimulation significantly inhibited the chemotactic activity of neutrophils. Furthermore, acute carrageenan-induced paw edema in mice was markedly inhibited by administration of Licochalcone A but not reduced Licochalcone A. Taken together, it is suggested that Licochalcone A is a promising anti-inflammatory drug in vivo and its fixed structure is critical for anti-inflammatory activity.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Chalcones/pharmacology , Edema/drug therapy , NF-kappa B/metabolism , Neutrophils/drug effects , Animals , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/chemistry , Carrageenan/administration & dosage , Chalcones/administration & dosage , Chalcones/chemistry , Chemokine CCL2/biosynthesis , Chemokine CCL2/genetics , Chemokine CXCL1/biosynthesis , Chemokine CXCL1/genetics , Chemotaxis/drug effects , Chemotaxis/immunology , Down-Regulation , Edema/chemically induced , Glycyrrhiza , Ketones/chemistry , Male , Mice , Mice, Inbred ICR , NF-kappa B/immunology , NIH 3T3 Cells , Neutrophils/pathology , Oxidation-ReductionABSTRACT
The metastasis of malignant tumor cells from the primary tumor to distant sites in the body is a complex process. To identify genes that may be essential for metastasis, we established poorly metastatic mouse melanoma cells, namely Y925F-mutated FAK-transfected cells (Y925F cells), from the highly metastatic mouse melanoma cell line B16F10, and performed expression analyses. The expression of phospholipid protein 2 (PLP2) was markedly down-regulated in the Y925F cells. To elucidate the function of PLP2, we established melanoma cells overexpressing PLP2. We found that PLP2 enhanced proliferation, adhesion, invasion, and MMP-2 secretion in vitro, and tumor metastasis in vivo. These results suggest that PLP2 aids metastasis. Furthermore, we showed that PLP2 binds specifically to PI3K, thus activating Akt.
Subject(s)
Melanoma, Experimental/genetics , Melanoma, Experimental/pathology , Myelin Proteolipid Protein/physiology , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Animals , Cell Adhesion/genetics , Cell Movement/genetics , Enzyme Activation , Gene Expression Regulation, Neoplastic , Lung Neoplasms/genetics , Lung Neoplasms/secondary , MARVEL Domain-Containing Proteins , Matrix Metalloproteinase 2/metabolism , Membrane Proteins , Mice , Mice, Inbred C57BL , Myelin Proteolipid Protein/genetics , Myelin Proteolipid Protein/metabolism , Neoplasm Metastasis , Oncogene Protein v-akt/metabolism , Phosphatidylinositol 3-Kinases/metabolism , Proteolipids , Rabbits , Tumor Cells, CulturedABSTRACT
It has been well established that disruption of JAK2 signaling regulation is involved in various hematopoietic disorders; however, the detailed mechanism by which abnormal activation of JAK2 exhibits transforming activity remains to be elucidated. Here, to clarify the functional role of the erythropoietin receptor (EpoR) and its downstream transcription factor STAT5 in the abnormal activation of JAK2-induced hematopoietic diseases, we generated a stable transfectant of Ba/F3 cells expressing EpoR and analyzed the molecular mechanism of how JAK2 mutation induces cell growth disorder. JAK2 V617F mutant exhibited transforming activity when EpoR was coexpressed. According to a study utilizing several truncated mutants of EpoR, the ability of EpoR to facilitate the transforming activity of JAK2 V617F mutant required the intracellular domain to interact with STAT5. Strikingly, once the truncated EpoR (EpoR-H) was mutated on Tyr-343, the phosphorylation of which is known to be important for interaction with STAT5, JAK2 V617F mutant failed to exhibit transforming activity, suggesting that STAT5 is critical for JAK2 mutant-induced hematopoietic disorder. Furthermore, the expression of the constitutively active STAT5 mutant exhibited transforming activity in Ba/F3 cells, and short hairpin RNA-mediated knockdown of STAT5 significantly inhibited the transforming activity of JAK2 V617F mutant. Taking these observations together, STAT5 plays an essential role in EpoR-JAK2 V617F mutant-induced hematopoietic disorder. Although it remains unclear why the presence of EpoR is required to activate oncogenic signaling via the JAK2 mutant and STAT5, its interacting ability is a target for the treatment of these hematopoietic diseases.
Subject(s)
Cell Transformation, Neoplastic/metabolism , Janus Kinase 2/metabolism , Mutation, Missense , Myeloproliferative Disorders/metabolism , Receptors, Erythropoietin/metabolism , STAT5 Transcription Factor/metabolism , Amino Acid Substitution , Animals , Cell Line , Cell Transformation, Neoplastic/genetics , Humans , Janus Kinase 2/genetics , Mice , Myeloproliferative Disorders/genetics , Protein Structure, Tertiary/genetics , Receptors, Erythropoietin/genetics , STAT5 Transcription Factor/geneticsABSTRACT
Glycyrrhiza inflata has been used as a traditional medicine with anti-inflammatory activity; however, its mechanism has not been fully understood. Licochalcone A is a major and biogenetically characteristic chalcone isolated from G. inflata. Here, we found that licochalcone A strongly inhibited tumor necrosis (TNF)-alpha-induced nuclear localization, DNA binding activity, and the transcriptional activity of nuclear factor-kappaB (NF-kappaB). Whereas licochalcone A had no effect on the recruitment of receptor-interacting protein 1 and IkappaB kinase beta (IKKbeta) to TNF receptor I by TNF-alpha, it significantly inhibited TNF-alpha-induced IkappaB kinase complex (IKK) activation and inhibitor of nuclear factor-kappaB degradation. It is interesting that we found that the cysteine residue at position 179 of IKKbeta is essential for licochalcone A-induced IKK inhibition, because licochalcone A failed to affect the kinase activity of the IKKbeta (C179A) mutant. In contrast, a structurally related compound, echinatin, failed to inhibit TNF-alpha-induced IKK activation and NF-kappaB activation, suggesting that the 1,1-dimethy-2-propenyl group in licochalcone A is important for the inhibition of NF-kappaB. In addition, TNF-alpha-induced expression of inflammatory cytokines CCL2/monocyte chemotactic protein-1and CXCL1/KC was clearly inhibited by licochalcone A but not echinatin. Taken together, licochalcone A might contribute to the potent anti-inflammatory effect of G. inflata through the inhibition of IKK activation.
Subject(s)
Chalcones/pharmacology , I-kappa B Kinase/antagonists & inhibitors , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Animals , Base Sequence , Cell Nucleus/metabolism , DNA Primers , Enzyme Activation , I-kappa B Kinase/metabolism , Mice , NIH 3T3 Cells , Reverse Transcriptase Polymerase Chain Reaction , Transcription, Genetic , Tumor Necrosis Factor-alpha/metabolismABSTRACT
JAK2 plays important roles in the regulation of a variety of cellular processes including cell migration, proliferation, and protection from apoptosis. Recently the L611S point mutation in JAK2 has been identified in a child with acute lymphoblastic leukemia. Here we analyzed the mechanism by which JAK2 exhibits its oncogenicity. In BaF3 murine hematopoietic cells, L611S mutant increased the expression of antiapoptotic proteins including X chromosome-linked inhibitor of apoptosis protein, inhibitor of apoptosis protein, and Bcl-XL. We also showed that JAK2 L611S mutant protects BaF3 cells from cytokine withdrawal-induced apoptotic cell death and leads to cytokine-independent cell growth. Furthermore BaF3 cells expressing JAK2 L611S mutant gained the ability to induce tumorigenesis in nude mice. The L611S mutant also exhibited malignancy, including prompt invasion and spreading into various organs, leading to rapid lethality of the mice. Finally we showed that a specific JAK2 inhibitor, AG490, potently inhibited cytokine-independent cell growth induced by JAK2 L611S mutant via the induction of apoptotic cell death. In addition, treatment with AG490 significantly inhibited the JAK2 L611S mutant-induced tumorigenesis in nude mice. Thus, our results both in vitro and in vivo strongly suggest that L611S mutant of JAK2 harbors potent oncogenic activity, and this probably requires the antiapoptotic signaling pathway.
Subject(s)
Janus Kinase 2/physiology , Liver Neoplasms, Experimental/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Splenic Neoplasms/etiology , Animals , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Blotting, Western , Cell Proliferation , Cytokines/metabolism , Flow Cytometry , Genetic Vectors , Hematopoietic Stem Cells/metabolism , Janus Kinase 2/antagonists & inhibitors , Liver Neoplasms, Experimental/drug therapy , Liver Neoplasms, Experimental/pathology , Lymphatic Metastasis , Mice , Mice, Inbred BALB C , Mice, Nude , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Neoplasm Invasiveness , Phosphorylation , Point Mutation , Proto-Oncogene Proteins c-akt/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , STAT5 Transcription Factor/metabolism , Splenic Neoplasms/drug therapy , Splenic Neoplasms/pathology , Transfection , Tyrphostins/pharmacologyABSTRACT
The somatic Jak2 mutation (V617F) was identified in most patients with polycythemia vera (PV). Here, we show that the activating Jak2 V617F mutant completely protected Ba/F3 cells from cytokine withdrawal-induced apoptotic cell death. Interestingly, Ba/F3 cells expressing Jak2 V617F mutant induced rapid tumorigenesis in nude mice, leading to rapid death. Whereas an injection of Ba/F3 cells expressing wild-type Jak2 had no effect, an injection of Ba/F3 cells expressing Jak2 V617F mutant promptly invaded and spread into various distinct organs, such as the liver and spleen. Strikingly, Jak2 inhibitor, AG490 potently inhibited cytokine-independent cell growth induced by the Jak2 V617F mutant. Also, treatment with AG490 effectively delayed Jak2 V617F mutant-induced tumorigenesis in nude mice. Thus, our results both in vitro and in vivo suggest that Jak2 harboring V617F mutation is a potent oncogene able to promote cell transformation and tumorigenesis.
Subject(s)
Hematopoietic Stem Cells/metabolism , Janus Kinase 2/metabolism , Polycythemia Vera/genetics , Animals , Apoptosis/drug effects , Apoptosis/genetics , Cell Line , Cell Transformation, Neoplastic/drug effects , Cell Transformation, Neoplastic/genetics , Genetic Predisposition to Disease , Hematopoietic Stem Cells/immunology , Hematopoietic Stem Cells/pathology , Janus Kinase 2/genetics , Liver/pathology , Mice , Mice, Nude , Mutation , Neoplasm Invasiveness , Neoplasm Transplantation , Polycythemia Vera/pathology , Polycythemia Vera/physiopathology , Polymorphism, Genetic , Spleen/pathology , Transfection , Tyrphostins/administration & dosageABSTRACT
Licorice root has been used as a traditional medicine for the treatment of gastric ulcer, bronchial asthma and inflammation. Licochalcone A is a major component of Xinjiang licorice, Glycyrrhiza inflata. Previously we showed that Licochalcone A significantly inhibited LPS-induced NF-kappaB transcriptional activation by abrogating the phosphorylation of NF-kappaB p65 at serine 276. Glycyrrhiza inflata contains not only Licochalcone A but also Licochalcone B, Licochalcone C, Licochalcone D, Echinatin and Isoliquiritigenin, harboring the common structure of chalcones. No chalcones had any effect on LPS-induced IkappaB degradation, nuclear translocation and DNA binding activity of NF-kappaB p65; however, we observed that Licochalcone B and Licochalcone D significantly inhibited LPS-induced phosphorylation at serine 276 and transcriptional activation of NF-kappaB, the same as Licochalcone A. Interestingly, we also found that Licochalcone A, Licochalcone B and Licochalcone D effectively inhibited LPS-induced activation of PKA, which is required for the phosphorylation of NF-kappaB p65 at serine 276. Consequently, Licochalcone B and Licochalcone D significantly reduced the LPS-induced production of NO, TNFalpha and MCP-1. On the other hand, Licochalcone C, Echinatin and Isoliquitigenin failed to inhibit LPS-induced NF-kappaB activation. These findings suggest that the anti-inflammatory effect of Glycyrrhiza inflata is ascribable to the potent inhibition of NF-kappaB by Licochalcone A, Licochalcone B and Licochalcone D.
Subject(s)
Chalcones/pharmacology , Cyclic AMP-Dependent Protein Kinases/metabolism , Transcription Factor RelA/metabolism , Animals , Cell Line , Chalcones/chemistry , Chemokine CCL2/antagonists & inhibitors , Chemokine CCL2/metabolism , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Glycyrrhiza/chemistry , Lipopolysaccharides/immunology , Macrophages/drug effects , Macrophages/immunology , Mice , Nitric Oxide/antagonists & inhibitors , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/antagonists & inhibitors , Nitric Oxide Synthase Type II/metabolism , Phosphorylation/drug effects , Pyrrolizidine Alkaloids/pharmacology , Signal Transduction , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Licorice root, Glycyrrhiza inflata, has been used as a traditional medicine for the treatment of bronchial asthma and inflammation; however, the mechanism of its anti-inflammatory activity has not been clarified. Here, we investigated the effect of Licochalcone A, a major component of G. inflata, on the LPS signaling pathway. We found that Licochalcone A remarkably inhibited LPS-induced NO production, and TNFalpha expression and MCP-1 expression in both RAW264.7 cells and primary macrophages. Furthermore, when injected with Licochalcone A prior to injection of LPS, the serum level of TNFalpha and MCP-1 in C57BL/6 mice was clearly decreased, indicating that Licochalcone A has a potent anti-inflammatory effect both in vitro and in vivo. Strikingly, Licochalcone A significantly inhibited LPS-induced NF-kappaB transcriptional activation; however, it had no effect on not only the phosphorylation and degradation of IkappaBalpha but also nuclear translocation and DNA binding activity of NF-kappaB p65. Interestingly, Licochalcone A markedly inhibited the phosphorylation of p65 at serine 276. As a result, it reduced NF-kappaB transactivation by preventing the interaction of p65 with p300. Taken together, Licochalcone A might contribute to the potent anti-inflammatory effect of G. inflata through the unique mechanism of NF-kappaB inhibition.
Subject(s)
Anti-Inflammatory Agents/pharmacology , Chalcones/pharmacology , Lipopolysaccharides/pharmacology , Transcription Factor RelA/metabolism , Animals , Cell Line , Chemokine CCL2/blood , Chemokine CCL2/metabolism , Glycyrrhiza/chemistry , Lipopolysaccharides/antagonists & inhibitors , Male , Mice , Mice, Inbred C57BL , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/metabolism , Phosphorylation , Serine/metabolism , Signal Transduction , Tumor Necrosis Factor-alpha/blood , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Atopic dermatitis (AD) is a chronic inflammatory skin disease, which is accompanied by marked increases in the levels of inflammatory cells, including mast cells and eosinophils as well as T cells and macrophages. To investigate the expression pattern of chemokines in AD, a house dust mite, Dermatophagoides farinae extracts (DfE)-induced NC/Nga AD model was developed in mice, and this model was used to determine the expression levels of chemokines in atopic lesions using DNA microarrays and RT-PCR. When NC/Nga mice were repeatedly treated with DfE for 4 to 7 weeks on the back skin, the mRNA expression levels of CCL20/LARC, CCL24/eotaxin-2, CCL17/TARC, and CCL11/eotaxin-1 were markedly induced and lesser of CCL2/MCP-1, within the inflammatory lesion of the back skin. Immunohistochemical staining revealed the expression of these chemokines in the epidermis and dermis of DfE-treated NC/Nga mice. Interestingly, repeated application of tacrolimus ointment potently inhibited DfE-induced atopic dermatitis in NC/Nga mice concomitant with the inhibition of these changes in chemokine gene and protein expression levels particularly of CCL20/LARC, CCL17/TARC, and CCL11/eotaxin-1. These data indicate that severe atopic dermatitis induced by DfE accompanies elevated chemokine levels, and it was proposed that tacrolimus ointment is beneficial for the treatment of severe AD.
Subject(s)
Chemokines/metabolism , Dermatitis, Atopic/drug therapy , Dermatophagoides farinae/immunology , Immunosuppressive Agents/administration & dosage , Tacrolimus/administration & dosage , Allergens/immunology , Animals , Chemokines/drug effects , Chemokines/immunology , Dermatitis, Atopic/immunology , Dermatitis, Atopic/pathology , Disease Models, Animal , Female , Immunoglobulin E/blood , Mice , OintmentsABSTRACT
TNF receptor-associated factor 6 (TRAF6) is an essential adaptor protein for the Interleukin-1 (IL-1) signaling pathway; however, its role in the signaling of another proinflammatory cytokine, tumor necrosis factor alpha (TNFalpha, has not been explored. Interestingly, we observed that TNFalpha-induced expression of IL-6, CXCL1 and granulocyte macrophage colony stimulating factor (GM-CSF) were significantly enhanced in TRAF6-deficient MEFs. Compared to those observed in wild-type MEFs, TNFalpha-induced IkappaB kinase (IKK) activation and IkappaBalpha degradation were enhanced in TRAF6-deficient MEFs. Also, TNFalpha-induced DNA binding activity and transcriptional activation of nuclear factor kappaB (NF-kappaB) were also augmented in TRAF6-deficient MEFs. On the other hand, TRAF6 deficiency did not affect the TNFalpha-induced activation of mitogen-activated protein (MAP) kinases, ERK, JNK, and p38. Moreover, the reintroduction of exogenous TRAF6 into TRAF6-deficient MEFs clearly suppressed TNFalpha-induced IKK activation, NF-kappaB activation and subsequent cytokine expression. In contrast, both the deletion mutant (DeltaN) and the point mutant (C70A) of TRAF6, which is defective in its ubiquitin ligase activity, failed to repress TNFalpha-induced IKK activation, NF-kappaB activation and cytokine production. Thus, these data suggest that TRAF6 negatively regulates TNFalpha-induced NF-kappaB activation through its ubiquitin ligase activity.
Subject(s)
NF-kappa B/metabolism , Signal Transduction/physiology , TNF Receptor-Associated Factor 6/metabolism , Tumor Necrosis Factor-alpha/metabolism , Animals , Cells, Cultured , Cytokines/genetics , Cytokines/metabolism , Enzyme Activation , Fibroblasts/cytology , Fibroblasts/physiology , Humans , I-kappa B Kinase/genetics , I-kappa B Kinase/metabolism , Mice , Mice, Knockout , Mitogen-Activated Protein Kinases/genetics , Mitogen-Activated Protein Kinases/metabolism , Mutation , NF-kappa B/genetics , Retroviridae/genetics , Retroviridae/metabolism , TNF Receptor-Associated Factor 6/geneticsABSTRACT
Aberrant activation of Jak/Stat signaling causes a number of hematopoietic disorders and oncogenesis, and therefore the effective inhibitors of the Jak/Stat signaling pathway may be therapeutically useful. TEL-Jak2 gene fusion, which has been identified in human leukemia, encodes a chimeric protein endowed with constitutive tyrosine kinase activity. Expression of TEL-Jak2 protects Ba/F3 cells from IL-3 withdrawal-induced apoptotic cell death and leads to IL-3-independent growth. However, its mechanisms remain to be only partially understood. Here, we first found that Licochalcone A, one of the flavonoids isolated from the root of Glycyrrhiza inflate, inhibited TEL-Jak2-mediated cell proliferation and survival in the absence of IL-3. Licochalcone A failed to inhibit the activity of TEL-Jak2, however, this induced apoptosis of TEL-Jak2-transformed cells with a much lower concentration in the absence of IL-3 than in the presence of IL-3. Interestingly, Licochalcone A significantly inhibited the phosphorylation and nuclear localization of Stat3, which is essential for TEL-Jak2-induced cell transformation. These data suggest that Licochalcone A is a specific inhibitor for Stat3 and would be employed for the treatment of various diseases caused by disorders of the Jak/Stat pathway.
Subject(s)
Cell Transformation, Neoplastic/drug effects , Chalcones/pharmacology , Oncogene Proteins, Fusion , STAT3 Transcription Factor/antagonists & inhibitors , Animals , Apoptosis/drug effects , Cell Line , Cell Proliferation/drug effects , Interleukin-3/pharmacology , Leukemia/prevention & control , Mice , Plant ExtractsABSTRACT
IL-33 has been shown to induce Th2 responses by signaling through the IL-1 receptor-related protein, ST2L. However, the signal transduction pathways activated by the ST2L have not been characterized. Here, we found that IL-33-induced monocyte chemoattractant protein (MCP)-1, MCP-3 and IL-6 expression was significantly inhibited in TNF receptor-associated Factor 6 (TRAF6)-deficient MEFs. IL-33 rapidly induced the formation of ST2L complex containing IL-1 receptor-associated kinase (IRAK), however, lack of TRAF6 abolished the recruitment of IRAK to ST2L. Consequently, p38, JNK and Nuclear factor-kappaB (NF-kappaB) activation induced by IL-33 was completely inhibited in TRAF6-deficient MEFs. On the other hand, IL-33-induced ERK activation was observed regardless of the presence of TRAF6. The introduction of TRAF6 restored the efficient activation of p38, JNK and NF-kappaB in TRAF6 deficient MEFs, resulting in the induction of MCP-1, MCP-3 and IL-6 expression. Moreover, IL-33 augmented autoubiquitination of TRAF6 and the reconstitution of TRAF6 mutant (C70A) that is defective in its ubiquitin ligase activity failed to restore IL-33-induced p38, JNK and NF-kappaB activation. Thus, these data demonstrate that TRAF6 plays a pivotal role in IL-33 signaling pathway through its ubiquitin ligase activity.
Subject(s)
Interleukins/metabolism , Signal Transduction , TNF Receptor-Associated Factor 6/metabolism , Animals , Carboxypeptidases A/genetics , Carboxypeptidases A/metabolism , Cell Line , Chemokine CCL2/genetics , Chemokine CCL2/metabolism , Fibroblasts/drug effects , Fibroblasts/enzymology , Gene Expression Regulation/drug effects , Humans , Interleukin-33 , Interleukin-6/genetics , Interleukin-6/metabolism , Interleukins/pharmacology , Mice , Mutant Proteins/metabolism , Signal Transduction/drug effects , TNF Receptor-Associated Factor 6/deficiency , Ubiquitin-Protein Ligases/metabolism , Ubiquitination/drug effectsABSTRACT
This study focused on the role of focal adhesion kinase (FAK), a cytoplasmic tyrosine kinase important for many cellular processes, in the proliferation, adhesion, and invasion of melanoma cells in vitro and in vivo. We found that the Y925F-mutation of FAK in B16F10 melanoma cells suppressed metastasis in an experimental model, which correlated well with decreased extracellular matrix dependent proliferative capability, adhesive, migrational, and invasive capabilities. Transduction of the mutation Y925F resulted in a down-regulation of the phosphorylation of Erk, the expression of VEGF, and the association of FAK with paxillin. The results provide clear evidence that 925Y of FAK is critical for melanoma metastasis and this phosphorylation site will be an anti-metastatic target.
Subject(s)
Cell Proliferation , Focal Adhesion Kinase 1/metabolism , Gene Expression Regulation, Neoplastic , Melanoma, Experimental/pathology , Mutation , Animals , Cell Adhesion , Cell Line, Tumor , Extracellular Matrix/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Focal Adhesion Kinase 1/genetics , Melanoma, Experimental/enzymology , Melanoma, Experimental/genetics , Mice , Mice, Inbred C57BL , Neoplasm Invasiveness , Neoplasm Metastasis , Paxillin/metabolism , Phosphorylation , Transfection , Vascular Endothelial Growth Factor A/metabolismABSTRACT
Celecoxib is a specific inhibitor of cyclooxygenase 2 (COX2). While it has been used for the treatment of chronic inflammatory conditions, including rheumatoid arthritis, its detailed anti-inflammatory mechanism has not been clarified. Here, we found that Celecoxib potently inhibited TNFalpha-induced transcriptional activity and DNA binding activity of NF-kappaB; however, Celecoxib had no effect on TNFalpha-induced IKK activation and degradation of IkappaBalpha and IkappaBbeta, suggesting that it inhibited NF-kappaB activation via suppressing downstream of IKK activation and IkappaBs degradation. Interestingly, it was also found that Celecoxib abrogated TNFalpha-induced nuclear accumulation of the NF-kappaB p65 subunit. As a result, TNFalpha-induced expression of inflammatory cytokines, CXCL1/KC and CCL2/MCP-1, was clearly inhibited by Celecoxib. On the other hand, Celecoxib had no effect on the TNFalpha-induced nuclear translocation of c-jun and activation of ERK, JNK, p38 and Akt. Taken together, these data indicate that Celecoxib specifically inhibits TNFalpha-induced NF-kappaB activation at the level of its nuclear translocation. This negative regulation of NF-kappaB activation by Celecoxib might be an important mechanism leading to its anti-inflammatory activity.
Subject(s)
Cell Nucleus/metabolism , Cyclooxygenase 2 Inhibitors/pharmacology , NF-kappa B/metabolism , Pyrazoles/pharmacology , Sulfonamides/pharmacology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Animals , Celecoxib , Electrophoretic Mobility Shift Assay , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Fluorescent Antibody Technique , Mice , NIH 3T3 Cells , Polymerase Chain Reaction , Protein Transport/drug effects , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Two types of amphoteric glycosphingolipid found in the earthworm Pheretima hilgendorfi, PC(-->6)-beta-d-Galp-(1-->6)-beta-d-Galp-(1-->1)Cer (1) and PC(-->6)-beta-d-Galp-(1-->6)-beta-d-Galp-(1-->6)-beta-d-Galp-(1-->1)Cer (2), and their derivatives (4, 5) were synthesized. These were examined for their ability to enhance production of interleukin-8 (IL-8), a potent inflammatory cytokine involved in neutrophil chemotaxis, in a TNFalpha-stimulated granulocytic HL-60 cells. Compounds 1 and 2 were found to be potent enhancers of IL-8 production.
Subject(s)
Glycosphingolipids/chemistry , Glycosphingolipids/chemical synthesis , Oligochaeta/metabolism , Animals , Carbohydrate Conformation , Carbohydrate Sequence , Chemotaxis , Cytokines/metabolism , HL-60 Cells , Humans , Inflammation , Interleukin-8/metabolism , Models, Biological , Models, Chemical , Molecular Conformation , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Numerous studies have demonstrated the participation of glicolipids in signal transduction and the regulation of melanoma cell growth and apoptosis. Hoping to discover new anticancer drugs, we have synthesized ten glycolipids found in various invertebrates that do not have sialic acids. These compounds were tested for antiproliferative effects on a melanoma cell line, B16F10. A synthetic compound, Manbeta(1-4)[Fucalpha(1-3)]Glcbeta1-Cer, (glycosphingolipid 7), which was identified in the millipede Parafontaria laminata armigera, had an antiproliferative effect on the melanoma cells. This compound suppressed the activation of the focal adhesion kinase (FAK)-Akt pathway as well as the activation of extracellular signal-regulated kinase (Erk)1/2 pathway involved in cell proliferation. Expression of the cell cycle proteins, cyclin D1 and CDK4, was suppressed by glycosphingolipid 7. From these results, glycosphingolipid 7 suppressed the activation of the FAK-Akt pathway and of Erk1/2, which resulted in a decrease in the expression of cyclin D1 and CDK4. Glycosphingolipid 7 might be a candidate for an inhibitor of cell proliferation in melanomas.